All canine diagnoses

Your dog was diagnosed with Appendicular Osteosarcoma. Most common primary bone tumour in dogs (~85% of skeletal tumours). Incidence 27× higher than in humans. ~90–95% of dogs have micrometastatic disease at diagnosis. Large and giant breeds overwhelmingly predisposed. Compare 7 treatment options for dogs including Amputation + Adjuvant Carboplatin, Amputation + Adjuvant Doxorubicin, Limb-Sparing Surgery + Adjuvant Chemotherapy — with survival times, costs, and what to expect during treatment.

🐕

Appendicular Osteosarcoma

Stage I (localised) – III (metastatic)

BreedsScottish DeerhoundLeonbergerGreat DaneRottweilerGreyhoundGerman Shepherd DogBoxerIrish WolfhoundSaint BernardLabrador Retriever
canine

Mesenchymal

About This Cancer

Osteosarcoma is the most common bone cancer in dogs, arising from bone-forming cells (osteoblasts) that begin to grow and divide uncontrollably. In the appendicular (limb) form, the tumour typically develops near the growth plates of the long bones — most often the radius (near the wrist) or the proximal humerus (shoulder area) in the forelimbs, and the distal femur or proximal tibia (around the knee) in the hind limbs. The disease is strongly associated with large and giant breeds such as Rottweilers, Great Danes, and Irish Wolfhounds. The tumour causes progressive bone destruction and pain, often presenting as worsening lameness. Critically, at the time of diagnosis, the overwhelming majority of dogs (roughly 90–95%) already have microscopic cancer cells that have spread to the lungs, even though these are too small to detect on X-rays. This is why treatment plans address both the primary tumour and this invisible distant disease.

Enneking Staging System (adapted for canine OSA)

Based on tumour grade, compartmental status, and presence of metastasis.

Stage ILow-grade tumour, no metastasis
Stage IIAHigh-grade, intracompartmental, no metastasis
Stage IIBHigh-grade, extracompartmental, no metastasis
Stage IIIAny grade with distant metastasis (usually pulmonary)
Prognostic Factors(6)
Serum alkaline phosphatase (SALP)Elevated SALP is a significant negative prognostic indicator. Dogs with elevated SALP at diagnosis have shorter DFI and MST.(BMC Vet Res meta-analysis, 2012)
Anatomical locationProximal humerus carries worst prognosis among appendicular sites. Distal radius has best prognosis and is most amenable to limb-sparing.(BMC Vet Res meta-analysis, 2012)
Histologic subtypeFibrosarcomatous subtype carries more favourable prognosis.(BMC Vet Res meta-analysis, 2012)
Body weightRisk increases with body weight. Giant breeds at highest risk.
Bone-specific alkaline phosphatase (BALP)Elevated BALP is a more specific prognostic marker than total SALP. Elevated BALP at diagnosis or persistent elevation post-treatment associated with shorter DFI and MST.(Ehrhart et al., 1998 (PMID 9570619))
Monocyte countElevated peripheral monocyte count at diagnosis associated with shorter survival. Reflects tumour-associated immunosuppressive microenvironment.(Sottnik et al., 2010)
Minimum Workup(7 steps)
1Orthogonal radiographs of affected limb
2Three-view thoracic radiographs (metastatic screening)
3Complete blood count and serum biochemistry (including serum ALP)
4Bone biopsy (histopathological confirmation — can be done at time of amputation)
5Regional lymph node assessment
6Abdominal ultrasound (optional — hepatic/splenic metastasis screening)
7Bone scan or CT (optional — to assess for skip metastases or polyostotic disease)

Median Survival Time Comparison

How long the average patient survives with each treatment

Bar opacity reflects evidence strength
Amputation + Adjuvant Carboplatin
~11 mo (9–13)
Amputation + Adjuvant Doxorubicin
~11 mo (8–12)
Limb-Sparing Surgery + Adjuvant Chemotherapy
~11 mo (2–11)
Stereotactic Radiation (SRS/SRT) + Adjuvant Chemotherapy
~7.8 mo (2.2–10.8)
Amputation Alone (No Adjuvant Chemotherapy)
~4.5 mo (4–5)
Palliative Radiation Therapy
~4.5 mo (3–6)
Bisphosphonate Therapy (Pamidronate/Zoledronate)
See notes
Reading this page: MST (Median Survival Time) is how long the average patient survives with a given treatment. ORR (Overall Response Rate) is the percentage of patients whose tumour shrank or disappeared. CR = Complete Response (tumour gone); PR = Partial Response (tumour shrank). Hover over any abbreviation for a quick explanation.
Strength of Evidence

Each treatment is rated by how much published research supports its use. Solid bars indicate stronger evidence; dashed bars mean less certainty.

StrongLarge published studies with strong agreement among veterinary oncologists.
ModerateWidely used in clinical practice, but supported by smaller or retrospective studies.
IndirectEvidence comes from a different tumour type or species and has been applied here.
LimitedVery little published data is available for this specific treatment.

Please note: All treatment data is sourced from published peer-reviewed literature. Survival times and cost figures are approximate guides. Your pet's individual factors — including tumour grade, stage, and overall health — will influence outcomes and should guide all treatment decisions. The strength-of-evidence rating reflects how much research exists, not how strongly a treatment is recommended. This tool is designed to help you have informed conversations with your veterinary oncologist, not to replace them. Costs shown are US referral centre estimates and may vary significantly by region.